Andreas Hohlbaum is a Ph.D. immunologist with extensive industry experience in R&D of antibodies and next-generation scaffold proteins. They have led preclinical development and non-clinical safety evaluations, contributing to the advancement of Anticalin and Nanobody programs from concept to regulatory approval. Currently, Andreas is the Head of Preclinical Safety R&D Projects at Sanofi, leading a team of toxicologists across multiple countries to implement safety strategies for drug candidates in global Immunology and Inflammation projects. Their previous roles include positions at Ablynx, Dyax, and Boston University School of Medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices